| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ORIGINAL PAPER |
Division of Neuro-Oncology, Department of Hematology-Oncology, St. Jude Childrens Research Hospital, Memphis, Tennessee, USA
Correspondence: Alberto Broniscer, M.D., Department of Hematology-Oncology, St. Jude Childrens Research Hospital, 332 North Lauderdale Room C-6066 Mail Stop 260, Memphis, Tennessee 38105, USA. Telephone: 901-495-4925; Fax: 901-521-9005; e-mail: alberto.broniscer{at}stjude.org
Pediatric high-grade gliomas represent a heterogeneous group of tumors that accounts for 15%20% of all pediatric central nervous system tumors. These neoplasms predominantly involve the supratentorial hemispheres or the pons, in which case the tumors are usually called diffuse brainstem gliomas. The diagnosis of supratentorial neoplasms is dependent on their histologic appearance. The maximum possible surgical resection is always attempted since the degree of surgical resection is the main prognostic factor for these patients. Older children (>3 years) with supratentorial neoplasms undergo a multimodality treatment comprised of surgical resection, radiation therapy, and chemotherapy. The addition of chemotherapy seems to improve the survival of a subset of these children, particularly those with glioblastoma multiforme. However, 2-year survival rates remain poor for children with supratentorial neoplasms, ranging from 10%30%.
The diagnosis of a diffuse brainstem glioma is based upon typical imaging, dispensing with the need for surgery in the majority of cases. Radiation therapy is the mainstay of treatment for children with diffuse brainstem gliomas. The role of chemotherapy for these children is not clear, and it is, in general, employed in the context of an investigational study. Less than 10% of children with diffuse brainstem gliomas survive 2 years.
Because the outcome for patients with either type of tumor is poor when standard multimodality therapy is used, these children are ideal candidates for innovative treatment approaches.
This article has been cited by other articles:
![]() |
H. K. Thorarinsdottir, M. Santi, R. McCarter, E. J. Rushing, R. Cornelison, A. Jales, and T. J. MacDonald Protein Expression of Platelet-Derived Growth Factor Receptor Correlates with Malignant Histology and PTEN with Survival in Childhood Gliomas Clin. Cancer Res., June 1, 2008; 14(11): 3386 - 3394. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Shu, K. K. Wong, J. M. Su, A. M. Adesina, L. T. Yu, Y. T. M. Tsang, B. C. Antalffy, P. Baxter, L. Perlaky, J. Yang, et al. Direct Orthotopic Transplantation of Fresh Surgical Specimen Preserves CD133+ Tumor Cells in Clinically Relevant Mouse Models of Medulloblastoma and Glioma Stem Cells, June 1, 2008; 26(6): 1414 - 1424. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. Ziegler, A. L. Kung, and M. W. Kieran Anti-Apoptosis Mechanisms in Malignant Gliomas J. Clin. Oncol., January 20, 2008; 26(3): 493 - 500. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Broniscer, S. J. Baker, A. N. West, M. M. Fraser, E. Proko, M. Kocak, J. Dalton, G. P. Zambetti, D. W. Ellison, L. E. Kun, et al. Clinical and Molecular Characteristics of Malignant Transformation of Low-Grade Glioma in Children J. Clin. Oncol., February 20, 2007; 25(6): 682 - 689. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. W. Newcomb, S. Demaria, Y. Lukyanov, Y. Shao, T. Schnee, N. Kawashima, L. Lan, J. K. Dewyngaert, D. Zagzag, W. H. McBride, et al. The Combination of Ionizing Radiation and Peripheral Vaccination Produces Long-term Survival of Mice Bearing Established Invasive GL261 Gliomas Clin. Cancer Res., August 1, 2006; 12(15): 4730 - 4737. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. DHODAPKAR, D. BANERJEE, and R. M. STEINMAN Harnessing the Immune System Against Human Glioma Ann. N.Y. Acad. Sci., December 1, 2005; 1062(1): 13 - 21. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Rosenblum Brain Stem Glioma: Two Case Studies Journal of Pediatric Oncology Nursing, March 1, 2005; 22(2): 114 - 118. [Abstract] [PDF] |
||||
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |